SOURCE: Alkermes

DESCRIPTION:

We are pleased to share clinical trial data on our investigational #immunooncology therapy and are excited to be a part of the 17th EADO Congress and 2021 World Mobile Congress Interactive Virtual Meeting. https://worldmelanoma2021.com/

Tweet me: .@Alkermes is pleased to share clinical trial data on their investigational #immunooncology therapy at the 17th EADO Congress and #WMC21 Interactive Virtual Meeting. https://bit.ly/3mLtdyG

KEYWORDS: NASDAQ:ALKS, Alkermes, Immuno-Oncology, 17th EADO Congress, 2021 World Mobile Congress Interactive Virtual Meeting